Intercept Pharma (ICPT) Misses Q4 EPS by $1.10, Revenue Tops Views

Intercept Pharma (NASDAQ: ICPT) reported Q4 EPS of ($4.84), $1.10 worse than the analyst estimate of ($3.74). Revenue for the quarter came in at $13 million versus the consensus estimate of $8.96 million.

For earnings history and earnings-related data on Intercept Pharma (ICPT) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Boost Run, Inc. (BRUN) Reports Q2 Revenue of $31.1M
• Reading (RDI) Tops Q2 EPS by 4c